



ASX / MEDIA RELEASE

23<sup>rd</sup> June 2015

## **Additional SIRFLOX Clinical Data to be presented at the 17<sup>th</sup> ESMO WCGIC Meeting in Barcelona, Spain**

**Sydney, Australia; 23<sup>rd</sup> June 2015** – Sirtex Medical Limited (ASX:SRX) is pleased to announce that additional SIRFLOX study data will be presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC) meeting from the 1<sup>st</sup> to the 4<sup>th</sup> of July 2015 in Barcelona, Spain.

Professor Guy Van Hazel, MD from the University of Western Australia and Co-Principal Investigator on the SIRFLOX Study will give an oral presentation entitled “A randomised, prospective phase III trial comparing SIRT with yttrium-90 resin microspheres plus (B) FOLFOX versus (B) FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer the SIRFLOX study” on Saturday, 4<sup>th</sup> of July.

“As we had indicated recently, the process of further data analysis, interpretation and presentation of SIRFLOX study information will continue well beyond the ASCO meeting. We are delighted the SIRFLOX study has been selected for an Oral presentation in the metastatic colorectal cancer session at such a prestigious congress,” commented Mr Gilman Wong, CEO of Sirtex Medical.

According to the WCGIC, the release of the abstracts for the meeting will be available for viewing from the *Annals of Oncology* Journal at the following days: 24<sup>th</sup> June 2015 – All Abstracts accepted for poster presentation and 30<sup>th</sup> June 2015 – All Abstracts including those accepted for Oral presentation.

### **About WCGIC**

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. It has been endorsed by leading professional societies and organizations.

### **About SIRFLOX**

The SIRFLOX study is an international, multi-centre, randomised controlled study that enrolled over 500 patients with mCRC whose disease was non-resectable and had spread to either the liver alone or the liver plus a limited number of sites outside the liver, including lymph nodes and the lungs. The study was conducted in more than 100 hospitals across Australia, Europe, Israel, New Zealand and the United States. SIRFLOX is the first, large randomised controlled study that has examined the use of Selective Internal Radiation Therapy (SIRT, also known as radioembolisation) in the treatment of colorectal liver metastases. For more information, please visit [www.sirflox.com](http://www.sirflox.com) and the ASX announcement made by Sirtex on 1<sup>st</sup> June 2015.

---

**Head Office**  
Level 33, 101 Miller Street  
North Sydney, NSW 2060  
Australia

**Americas**  
300 Unicorn Park Drive  
Woburn, MA 01801  
United States

**Europe, Middle East & Africa**  
Josef-Schumpeter-Allee 33  
53227 Bonn  
Germany

**Asia Pacific**  
50 Science Park Road, #01-01  
The Kendall Science Park II  
Singapore 117406

## **About SIR-Spheres® Y-90 Resin Microspheres**

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy or SIRT (also known as radioembolisation), a proven technology for inoperable liver tumours that delivers substantial, targeted doses of radiation directly to the cancer. Key SIR-Spheres Y-90 resin microspheres regulatory approvals include Pre-Market Approval (PMA) from the US FDA, European Union (CE Mark) approval and Australian TGA approval.

## **About Sirtex Medical**

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. Approximately 50,000 doses have been supplied to treat patients with liver cancer at more than 800 medical centres in over 40 countries. For more information please visit [www.sirtex.com](http://www.sirtex.com).

For further information please contact:

### **Investor Enquiries:**

Mr Gilman Wong  
CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy  
Global Investor Relations Manager  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

### **Media Enquiries:**

Tim Allerton or Andrew Geddes  
City PR  
Phone: +61 (0) 2 9267 4511

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd